DUBLIN–(BUSINESS WIRE)–The “Global
Neuroblastoma Clinical Trial Pipeline Highlights – 2019” report
has been added to ResearchAndMarkets.com’s offering.
Neuroblastoma Pipeline Highlights – 2019 provides the most up-to-date
information on key pipeline products in the global Neuroblastoma market.
It covers emerging therapies for Neuroblastoma in active clinical
development stages including early and late stage clinical trials. The
pipeline data presented in this report helps executives for tracking
competition, identifying partners, evaluating opportunities, formulating
business development strategies, and executing in-licensing and
out-licensing deals.
Clinical Trial Stages:
The report provides Neuroblastoma pipeline products by clinical trial
stages including both early and late stage development – phase 3
clinical trials, phase 2 clinical trials, phase 1 clinical trials,
preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Neuroblastoma pipeline products by their dominant
mechanism of action/drug class. This helps executives categorize
products based on their drug class and also assess the strengths and
weaknesses of compounds.
Company:
The report provides Neuroblastoma pipeline products by the company.
Short-term Launch Highlights:
Find out which Neuroblastoma pipeline products will be launched in the
US and Ex-US till 2024.
Key Topics Covered:
1. Neuroblastoma Pipeline by Stages
2. Neuroblastoma Phase 3 Clinical Trial Insights
3. Neuroblastoma Phase 2 Clinical Trial Insights
4. Neuroblastoma Phase 1 Clinical Trial Insights
5. Neuroblastoma Preclinical Research Insights
6. Neuroblastoma Discovery Stage Insights
7. Appendix
8. Research Methodology
For more information about this report visit https://www.researchandmarkets.com/r/chzdsm
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs, Brain
Cancer Drugs, Clinical
Trials